Pioglitazone is a valid alternative to rosiglitazone

Research output: Contribution to journalArticle

Abstract

In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good glycemic control in patients with T2DM. Despite their efficacy, there was increasing concern regarding the potential of an increased cardiovascular risk with rosiglitazone. This resulted in the suspension of rosiglitazone from the European market by the European Medicines Agency in September 2010. This article focuses on the various steps that led to this important decision, and discusses a possible alternative for the treatment of patients receiving rosiglitazone.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalAmerican Journal of Cardiovascular Drugs
Volume11
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

rosiglitazone
pioglitazone
Type 2 Diabetes Mellitus
Thiazolidinediones
Hypoglycemic Agents
Suspensions
Therapeutics

Keywords

  • pioglitazone
  • rosiglitazone
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Pioglitazone is a valid alternative to rosiglitazone. / Derosa, Giuseppe.

In: American Journal of Cardiovascular Drugs, Vol. 11, No. 6, 2011, p. 357-362.

Research output: Contribution to journalArticle

@article{cc4e14921a574c02bb6a65f1c4f8c8a2,
title = "Pioglitazone is a valid alternative to rosiglitazone",
abstract = "In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good glycemic control in patients with T2DM. Despite their efficacy, there was increasing concern regarding the potential of an increased cardiovascular risk with rosiglitazone. This resulted in the suspension of rosiglitazone from the European market by the European Medicines Agency in September 2010. This article focuses on the various steps that led to this important decision, and discusses a possible alternative for the treatment of patients receiving rosiglitazone.",
keywords = "pioglitazone, rosiglitazone, type 2 diabetes mellitus",
author = "Giuseppe Derosa",
year = "2011",
doi = "10.2165/11595990-000000000-00000",
language = "English",
volume = "11",
pages = "357--362",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Pioglitazone is a valid alternative to rosiglitazone

AU - Derosa, Giuseppe

PY - 2011

Y1 - 2011

N2 - In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good glycemic control in patients with T2DM. Despite their efficacy, there was increasing concern regarding the potential of an increased cardiovascular risk with rosiglitazone. This resulted in the suspension of rosiglitazone from the European market by the European Medicines Agency in September 2010. This article focuses on the various steps that led to this important decision, and discusses a possible alternative for the treatment of patients receiving rosiglitazone.

AB - In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good glycemic control in patients with T2DM. Despite their efficacy, there was increasing concern regarding the potential of an increased cardiovascular risk with rosiglitazone. This resulted in the suspension of rosiglitazone from the European market by the European Medicines Agency in September 2010. This article focuses on the various steps that led to this important decision, and discusses a possible alternative for the treatment of patients receiving rosiglitazone.

KW - pioglitazone

KW - rosiglitazone

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=83055198551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055198551&partnerID=8YFLogxK

U2 - 10.2165/11595990-000000000-00000

DO - 10.2165/11595990-000000000-00000

M3 - Article

C2 - 21950735

AN - SCOPUS:83055198551

VL - 11

SP - 357

EP - 362

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 6

ER -